Skip to content

Clinical study on the effect of Edaravone and dexcamphenol on the level of inflammatory factors in patients with cerebral ischemia after acute craniocerebral injury

Clinical study on the effect of Edaravone and dexcamphenol on the level of inflammatory factors in patients with cerebral ischemia after acute craniocerebral injury

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054430
Enrollment
Unknown
Registered
2021-12-17
Start date
2021-12-30
Completion date
Unknown
Last updated
2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute craniocerebral injury

Interventions

Control group:Routine treatment of acute craniocerebral trauma (hemostasis, dehydration, intracranial pressure reduction, etc.)
Experimental group:Edaravone and dexcamphenol

Sponsors

Longyan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized in our hospital, new (60 cases) patients with acute craniocerebral injury were admitted to the hospital within 3 days of onset; 2. Aged 18 to 80 years; 3. Patients who have been diagnosed with brain injury by head CT or MRI and meet the diagnostic criteria for acute different degrees of traumatic brain injury.

Exclusion criteria

Exclusion criteria: 1. Patients with severe endocrine diseases; 2. Hejing severe organ failure (heart, liver and kidney failure); 3. Patients with severe respiratory infection and other organ infection in Hejing; 4. Patients with moderate or higher anemia or coagulation dysfunction or other serious blood system diseases; 5. Simple cerebrovascular accident, such as cerebral hemorrhage, cerebral infarction, cerebrovascular malformation and other diseases; 6. Patients with autoimmune system diseases; 7. Patients with malignant tumor in Hejing; 8. Patients or patient guardians are unwilling to participate in the project; 9. Other situations that are not suitable for inclusion in the group.

Design outcomes

Primary

MeasureTime frame
inflammatory factors;

Countries

China

Contacts

Public ContactHou Jianjin

Longyan People's Hospital

jamekinghou2001@163.com+86 13860201381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026